Clinical Trials Browser

Completed × Pharmacogenomic Variants × Clear all

Diffuse Intrinsic Pontine Glioma, Glioma

NCT03259503 2025-11-10

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Phase 1 Completed

50 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03300557 2025-08-29

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

Phase 2 Completed

40 enrolled 13 charts

Gynecologic

Endometrial Hyperplasia, Endometrial Neoplasms

NCT03508570 2025-05-22

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Phase 1 Completed

26 enrolled

Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

NCT03552471 2025-02-13

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 1 Completed

25 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03370718 2024-12-10

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

Phase 2 Completed

18 enrolled 5 charts

Adrenal Cortex Neoplasms

NCT03542695 2024-06-24

64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy

Phase EARLY_PHASE1 Completed

1 enrolled

Breast

Breast Neoplasms, Calcinosis

NCT03013933 2024-02-22

Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1 Completed

29 enrolled

Lymphoid

Hodgkin Disease

NCT03477396 2024-02-20

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

Phase 2 Completed

2 enrolled 13 charts

Breast

Estrogen Receptor and/or Progesterone Receptor Positive

NCT03520842 2023-08-01

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

Phase 2 Completed

22 enrolled 20 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03756818 2023-02-28

TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

52 enrolled

Gynecologic

Ovarian Neoplasms

Clinical Trials

CILENT

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy

Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors